tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE) and Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on aTyr Pharma (LIFEResearch Report) and Gilead Sciences (GILDResearch Report) with bullish sentiments.

aTyr Pharma (LIFE)

In a report issued on March 14, Kennen MacKay from RBC Capital maintained a Buy rating on aTyr Pharma, with a price target of $22.00. The company’s shares closed last Tuesday at $4.75, close to its 52-week low of $3.50.

According to TipRanks.com, MacKay is a 4-star analyst with an average return of 9.1% and a 51.9% success rate. MacKay covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Viracta Therapeutics, and Nurix Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for aTyr Pharma with a $11.00 average price target, implying a 134.0% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.

See the top stocks recommended by analysts >>

Gilead Sciences (GILD)

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Gilead Sciences, with a price target of $77.00. The company’s shares closed last Tuesday at $58.32, close to its 52-week low of $57.32.

According to TipRanks.com, Abrahams is a 1-star analyst with an average return of -1.1% and a 43.6% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $71.65, representing a 22.6% upside. In a report issued on March 1, Jefferies also maintained a Buy rating on the stock with a $80.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LIFE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed